Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Hepatocellular 5Recurrence 3Hepatitis B 3Lymphoma 2Virus Diseases 1Neoplasms 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Extensive Stage Lung Small Cell Carcinoma 1Colorectal Neoplasms 1

Interventions

thymoglobulin 1Tenofovir 1Rituximab 1Radiotherapy, Intensity-Modulated 1Oncolytic Virotherapy 1Nimorazole 1Lamivudine 1Kidney Transplantation 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Fluorescent Antibody Technique 1Cyclophosphamide 1Cisplatin 1Blood Specimen Collection 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Virus Diseases × Lamivudine × Clear all
NCT01528865 2016-03-11

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

University of Michigan Rogel Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡